| scholarly article | Q13442814 |
| P50 | author | Elizabeth Winzeler | Q42433498 |
| P2093 | author name string | Arnab K Chatterjee | |
| Erika L Flannery | |||
| P2860 | cites work | Global malaria mortality between 1980 and 2010: a systematic analysis | Q20905423 |
| Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaedit | Q21032449 | ||
| Immune mechanisms in malaria: new insights in vaccine development | Q21032484 | ||
| CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine | Q21034109 | ||
| The international limits and population at risk of Plasmodium vivax transmission in 2009 | Q21144525 | ||
| That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda | Q22061808 | ||
| Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites | Q47915637 | ||
| Study on the treatment of Plasmodium cynomolgi infections of the macaque with ketotifen | Q47916925 | ||
| Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum | Q47975339 | ||
| A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes | Q47991005 | ||
| Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses. | Q48005674 | ||
| The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase | Q48012548 | ||
| Comparative Antimalarial Activities and ADME Profiles of Ozonides (1,2,4-trioxolanes) OZ277, OZ439, and Their 1,2-Dioxolane, 1,2,4-Trioxane, and 1,2,4,5-Tetraoxane Isosteres | Q58866626 | ||
| Chromatographic profiling and identification of two new iridoid-indole alkaloids by UPLC–MS and HPLC-SPE-NMR analysis of an antimalarial extract from Nauclea pobeguinii | Q59306489 | ||
| Antimalarial drugs: Speeding to a new lead | Q82213667 | ||
| Beyond insecticides: new thinking on an ancient problem | Q38081702 | ||
| Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. | Q38465613 | ||
| Imidazolopiperazines: hit to lead optimization of new antimalarial agents. | Q39530026 | ||
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. | Q39616001 | ||
| Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 1: a clinical phase IIA trial | Q39685697 | ||
| Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic | Q39730747 | ||
| The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria | Q40573522 | ||
| Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. | Q40815903 | ||
| Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase | Q41176096 | ||
| Radical Cure of Infections with Plasmodium cynomolgi: a Function of Total 8-Aminoquinoline Dose * | Q41351570 | ||
| A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection | Q41925849 | ||
| The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance | Q41934155 | ||
| Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract | Q41935838 | ||
| The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. | Q41936641 | ||
| Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys | Q42115534 | ||
| If artemisinin drugs fail, what's plan B? | Q43064129 | ||
| Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial | Q43086319 | ||
| Malaria eradication back on the table | Q43174957 | ||
| Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications | Q43280343 | ||
| Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay | Q43571629 | ||
| Assessing transmission blockade in Plasmodium spp. | Q44165859 | ||
| A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines | Q44166008 | ||
| Impact of high-throughput screening in biomedical research | Q45352809 | ||
| First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children | Q46182948 | ||
| Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action. | Q46237143 | ||
| Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 2: a clinical phase IIB trial | Q47207567 | ||
| Inhibition of the development of the hepatic stages of Plasmodium yoelii nigeriensis by antihistaminic agents | Q47858470 | ||
| Artemisinin Resistance in Plasmodium falciparum Malaria | Q22061852 | ||
| Identification of an antimalarial synthetic trioxolane drug development candidate | Q22061876 | ||
| Thousands of chemical starting points for antimalarial lead identification | Q24289329 | ||
| Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study | Q24598695 | ||
| Spiroindolones, a potent compound class for the treatment of malaria | Q24606915 | ||
| Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug | Q24613311 | ||
| Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes | Q24651549 | ||
| Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum | Q24653974 | ||
| Global phenotypic screening for antimalarials | Q26824875 | ||
| Designing the next generation of medicines for malaria control and eradication | Q26859195 | ||
| Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal model | Q27314759 | ||
| Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model | Q27664030 | ||
| Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential | Q27670499 | ||
| Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target | Q27674154 | ||
| ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase | Q27675589 | ||
| Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery | Q27861956 | ||
| Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles | Q27973498 | ||
| Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials | Q27976482 | ||
| A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 | ||
| A plant-derived morphinan as a novel lead compound active against malaria liver stages | Q28469086 | ||
| A research agenda for malaria eradication: drugs | Q28476806 | ||
| The next opportunity in anti-malaria drug discovery: the liver stage | Q28477177 | ||
| Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery | Q28477602 | ||
| The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites | Q28480979 | ||
| Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay | Q28482292 | ||
| Human infections and detection of Plasmodium knowlesi | Q28709120 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| How were new medicines discovered? | Q29616641 | ||
| Chemical genetics of Plasmodium falciparum | Q29617272 | ||
| Validation of isoleucine utilization targets in Plasmodium falciparum | Q30045658 | ||
| Natural products as starting points for future anti-malarial therapies: going back to our roots? | Q30396384 | ||
| High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase | Q31156888 | ||
| Resistance to therapies for infection by Plasmodium vivax | Q33481576 | ||
| Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum | Q33567066 | ||
| Liver-stage malaria parasites vulnerable to diverse chemical scaffolds | Q36001246 | ||
| The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector | Q36086489 | ||
| The global pipeline of new medicines for the control and elimination of malaria | Q36320249 | ||
| Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors | Q36327112 | ||
| Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia | Q36512312 | ||
| First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials | Q36573154 | ||
| The silent path to thousands of merozoites: the Plasmodium liver stage | Q36623691 | ||
| Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate | Q36702987 | ||
| In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen | Q36736936 | ||
| Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa | Q36794459 | ||
| Tafenoquine: a promising new antimalarial agent | Q36802630 | ||
| Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria | Q36825513 | ||
| Cardiotoxicity of antimalarial drugs | Q36889570 | ||
| Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. | Q36942827 | ||
| Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins | Q37049536 | ||
| Sex in Plasmodium: a sign of commitment | Q37110637 | ||
| Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia | Q37253966 | ||
| Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission | Q37318117 | ||
| Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice | Q37352712 | ||
| The global portfolio of new antimalarial medicines under development. | Q37464688 | ||
| Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children | Q37612067 | ||
| A pre-emptive strike against malaria's stealthy hepatic forms | Q37624398 | ||
| Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design | Q37852563 | ||
| Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). | Q33598591 | ||
| An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS | Q33598760 | ||
| A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold | Q33630572 | ||
| Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. | Q33632425 | ||
| Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds | Q33682916 | ||
| Malaria parasite development in the mosquito and infection of the mammalian host | Q33738231 | ||
| A Research Agenda to Underpin Malaria Eradication | Q33818020 | ||
| The design and application of target-focused compound libraries | Q33882226 | ||
| Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription | Q33979085 | ||
| Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening | Q34122581 | ||
| 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential | Q34184919 | ||
| The impact of drug-induced QT interval prolongation on drug discovery and development | Q34201433 | ||
| Imidazolopiperazines: lead optimization of the second-generation antimalarial agents | Q34270117 | ||
| Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin | Q34306714 | ||
| Quinolone-3-diarylethers: a new class of antimalarial drug. | Q34334269 | ||
| Wolbachia invades Anopheles stephensi populations and induces refractoriness to Plasmodium infection | Q34343949 | ||
| A class of tricyclic compounds blocking malaria parasite oocyst development and transmission | Q34467923 | ||
| Whole-cell in vitro screening for gametocytocidal compounds | Q34509609 | ||
| Optimization of endochin-like quinolones for antimalarial activity | Q34511259 | ||
| Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays | Q34618434 | ||
| Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria | Q34693880 | ||
| A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue | Q34786064 | ||
| A high-throughput screen targeting malaria transmission stages opens new avenues for drug development | Q34833899 | ||
| Primaquine revisited six decades after its discovery | Q34859798 | ||
| Discovery of dual function acridones as a new antimalarial chemotype | Q34974896 | ||
| Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice | Q35071496 | ||
| Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion | Q35105092 | ||
| The hemolytic effect of primaquine and related compounds: a review | Q35274720 | ||
| A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor | Q35563452 | ||
| Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue | Q35571456 | ||
| Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen | Q35598598 | ||
| A major genome region underlying artemisinin resistance in malaria | Q35969854 | ||
| Characterization of Plasmodium liver stage inhibition by halofuginone | Q35983791 | ||
| P2507 | corrigendum / erratum | Erratum: Antimalarial drug discovery — approaches and progress towards new medicines | Q59546312 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| drug discovery | Q1418791 | ||
| P304 | page(s) | 849-862 | |
| P577 | publication date | 2013-11-11 | |
| P1433 | published in | Nature Reviews Microbiology | Q1071797 |
| P1476 | title | Antimalarial drug discovery - approaches and progress towards new medicines | |
| P478 | volume | 11 |
| Q28547546 | A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery |
| Q37017711 | A broad analysis of resistance development in the malaria parasite |
| Q34434145 | A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers |
| Q27861944 | A genomic and evolutionary approach reveals non-genetic drug resistance in malaria |
| Q104459037 | A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1 |
| Q47971927 | ATPase activity of Plasmodium falciparum MLH is inhibited by DNA-interacting ligands and dsRNAs of MLH along with UvrD curtail malaria parasite growth |
| Q38482862 | Advances in molecular genetic systems in malaria |
| Q27861933 | Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo |
| Q34456807 | Antimalarial compounds in Phase II clinical development. |
| Q88585860 | Antimalarial drug discovery - approaches and progress towards new medicines |
| Q34742823 | Antimicrobial peptides: a new class of antimalarial drugs? |
| Q92990319 | Antiplasmodial Activity and In Vivo Bio-Distribution of Chloroquine Molecules Released with a 4-(4-Ethynylphenyl)-Triazole Moiety from Organometallo-Cobalamins |
| Q28077952 | Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification |
| Q27319073 | Asparagine requirement in Plasmodium berghei as a target to prevent malaria transmission and liver infections |
| Q52606042 | Bioinspired synthesis of pentacyclic onocerane triterpenoids. |
| Q92689397 | CXCR4 regulates Plasmodium development in mouse and human hepatocytes |
| Q46388190 | Carbon-14 radiolabeling and tissue distribution evaluation of MMV390048. |
| Q34541909 | Chemical interrogation of the malaria kinome |
| Q52590901 | Chemical probes and drug leads from advances in synthetic planning and methodology. |
| Q89930493 | Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors |
| Q46412498 | Computer-Aided Drug Discovery from Marine Compounds: Identification of the Three-Dimensional Structural Features Responsible for Antimalarial Activity. |
| Q48193293 | Concise Total Synthesis of Dioncophylline E through an ortho-Arylation Strategy |
| Q58854227 | Contribution of Natural Products to Drug Discovery in Tropical Diseases |
| Q36951722 | Current therapies and future possibilities for drug development against liver-stage malaria |
| Q57019124 | Development of medicines for the control and elimination of malaria |
| Q30041606 | Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase |
| Q35868585 | Discovery of Dual-Stage Malaria Inhibitors with New Targets |
| Q35457856 | Diversity-oriented synthesis and activity evaluation of substituted bicyclic lactams as anti-malarial against Plasmodium falciparum |
| Q27861934 | Diversity-oriented synthesis yields novel multistage antimalarial inhibitors |
| Q90208087 | Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development |
| Q59546312 | Erratum: Antimalarial drug discovery — approaches and progress towards new medicines |
| Q36124336 | Ex Vivo Maturation Assay for Testing Antimalarial Sensitivity of Rodent Malaria Parasites |
| Q38227796 | From crystal to compound: structure-based antimalarial drug discovery |
| Q38735109 | Genetic diversity of next generation antimalarial targets: A baseline for drug resistance surveillance programmes |
| Q90324949 | Genetic validation of Leishmania genes essential for amastigote survival in vivo using N-myristoyltransferase as a model |
| Q28829342 | High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria |
| Q47200073 | Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity |
| Q47158353 | Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity† †The authors declare no competing interests. ‡ ‡Electronic supplementary information (ESI) available: Supple |
| Q53688052 | Humanized Mouse Models for the Study of Human Malaria Parasite Biology, Pathogenesis, and Immunity. |
| Q46252657 | Humanized mouse models infected with human Plasmodium species for antimalarial drug discovery |
| Q97535589 | Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update |
| Q28548496 | Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening |
| Q64060897 | Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering |
| Q42212171 | Identification of inhibitors of Plasmodium falciparum RuvB1 helicase using biochemical assays |
| Q35584827 | Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation |
| Q27683596 | In Vitro Resistance Selections for Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered Growth |
| Q56343057 | In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1) |
| Q36952275 | In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents |
| Q37680691 | Infection of laboratory-colonized Anopheles darlingi mosquitoes by Plasmodium vivax. |
| Q37721293 | Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review |
| Q35031730 | Isoprenoid precursor biosynthesis is the essential metabolic role of the apicoplast during gametocytogenesis in Plasmodium falciparum |
| Q56348671 | Low and heterogeneous prevalence of glucose-6-phosphate dehydrogenase deficiency in different settings in Ethiopia using phenotyping and genotyping approaches |
| Q48007457 | Malaria medicines to address drug resistance and support malaria elimination efforts |
| Q38497838 | Malaria medicines: a glass half full? |
| Q92990135 | Malaria: The Past and the Present |
| Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
| Q64106564 | Modular, stereocontrolled C-H/C-C activation of alkyl carboxylic acids |
| Q27861952 | Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials |
| Q30047024 | Mutations in the Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL) Confer Multidrug Resistance |
| Q42803189 | N-methylimidazole promotes the reaction of homophthalic anhydride with imines. |
| Q55429507 | Nanopore sequencing of drug-resistance-associated genes in malaria parasites, Plasmodium falciparum. |
| Q35671066 | Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery |
| Q38260909 | New insight-guided approaches to detect, cure, prevent and eliminate malaria |
| Q36723089 | On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry |
| Q26883657 | Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles |
| Q48020714 | Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation |
| Q57790745 | Orally Effective Aminoalkyl 10H-Indolo-[3,2-b]quinoline-11-carboxamide Kills the Malaria Parasite by Inhibiting Host Hemoglobin Uptake |
| Q36209383 | Pathogenesis of cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches |
| Q39321120 | Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles |
| Q38849773 | Phenotypic Screens in Antimalarial Drug Discovery |
| Q37414137 | Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes |
| Q35140796 | Plasmodium falciparum UvrD activities are downregulated by DNA-interacting compounds and its dsRNA inhibits malaria parasite growth |
| Q90107130 | Quantitative structure-activity relationship to predict the anti-malarial activity in a set of new imidazolopiperazines based on artificial neural networks |
| Q47852744 | Realistically, how far are we from a universal malaria drug? |
| Q40928786 | Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy |
| Q58781866 | Screening for potential prophylactics targeting sporozoite motility through the skin |
| Q58090912 | Steered molecular dynamics simulations reveal critical residues for (un)binding of substrates, inhibitors and a product to the malarial M1 aminopeptidase |
| Q56366132 | Structurally simple synthetic 1, 4-disubstituted piperidines with high selectivity for resistant Plasmodium falciparum |
| Q40116264 | Synergistic blending of high-valued heterocycles inhibits growth of Plasmodium falciparum in culture and P. berghei infection in mouse model |
| Q57496665 | Synthesis and Study of the Antimalarial Cardamom Peroxide |
| Q58035030 | Synthesis of cyclohexapeptides as antimalarial and anti-trypanosomal agents |
| Q26741307 | Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date |
| Q46322657 | Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets |
| Q35767057 | Teaching old drugs new tricks to stop malaria invasion in its tracks |
| Q36051237 | The Redox Cycler Plasmodione Is a Fast-Acting Antimalarial Lead Compound with Pronounced Activity against Sexual and Early Asexual Blood-Stage Parasites |
| Q47988678 | The antimalarial action of FK506 and rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35. |
| Q92391181 | The antimalarial screening landscape-looking beyond the asexual blood stage |
| Q36362906 | The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs |
| Q41149881 | The threat of antimalarial drug resistance |
| Q37101499 | Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials |
| Q59279549 | Uncovering new structural insights for antimalarial activity from cost-effective aculeatin-like derivatives |
| Q41588963 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria |
| Q59546312 | Erratum: Antimalarial drug discovery — approaches and progress towards new medicines | main subject | P921 |
Search more.